Congress backs expanded vaccine funding for world's poorest children
H.Res. 848 — Supporting the role of the United States in helping save the lives of children and protecting the health of people in low-income countries with vaccines and immunization through Gavi, the Vaccine Alliance ("Gavi"). · Filed by Thomas Kean (R-NJ) · 8 cosponsors · Introduced Oct 31, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This House resolution expresses support for continued U.S. funding and participation in Gavi, the Vaccine Alliance, a public-private partnership that delivers vaccines to children in low-income countries. The resolution documents Gavi's track record (1.1 billion children immunized, 18.8 million deaths averted since 2000) and calls on the U.S. government to increase its financial commitment to Gavi's 2026–2030 strategic cycle, particularly for malaria vaccine expansion.
Why we flagged it
This is a non-binding expression of support for continued U.S. participation in and funding of Gavi, a multilateral vaccine-delivery partnership. It contains no legislative mechanism, appropriation, or mandate—only affirmations and encouragements to the executive branch.
What the text implies
- Resolution does not appropriate funds or mandate spending; it is advisory only. Actual budget impact depends on separate appropriations decisions by Congress and executive discretion.
- Support for Gavi indirectly benefits vaccine manufacturers (Pfizer, GSK, Moderna, etc.) by expanding markets and creating predictable demand in low-income countries, though this is a secondary effect of the public health goal.
- Emphasis on malaria vaccine expansion (50M doses by 2030) signals potential market opportunity for malaria vaccine producers, particularly as WHO estimates demand at 80–100M doses annually by 2030.
Who it affects
The resolution supports funding for a demonstrably cost-effective global health intervention (returning $54 per $1 invested) that saves children's lives, reduces infectious disease prevalence globally, and strengthens U.S. health security by preventing disease outbreaks at their source. Ordinary Americans benefit from reduced pandemic risk and lower disease burden.
Who stands to gain
- vaccine manufacturers (Pfizer, GSK, Moderna, Merck, Serum Institute of India)
- cold chain equipment suppliers
- global health NGOs and implementing partners
Named in the bill
Gavi, the Vaccine Alliance, U.S. Department of State, Centers for Disease Control and Prevention (CDC), UNICEF, World Health Organization (WHO), World Bank, Bill & Melinda Gates Foundation, Global Polio Eradication Initiative, COVAX, Pfizer, GSK, Merck — and 2 more
Where it stands
8 cosponsors: 5 Democrats, 3 Republicans.
- Oct 31, 2025 — Referred to House Committee on Foreign Affairs · Congress.gov: “Referred to the House Committee on Foreign Affairs”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
How this was measured
Analysis — Quorum's AI read the full bill text on Jul 6, 2026; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
As of — page rendered 2026-10-20.
“Congress backs expanded vaccine funding for world's poorest children” QuorumCivic. https://share.quorumcivic.app/bill/119/hres848 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.